Arrowhead Pharmaceuticals Income Statement (2010-2026) | ARWR

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	45.89M	38.28M	27.44M	151.81M	32.41M	31.57M	62.55M	146.27M	15.82M	16.10M	3.55M				2.50M	542.71M	27.77M	256.47M	264.03M	73.74M
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)	59.33M	65.77M	65.77M	75.98M	72.18M	83.38M	83.69M	74.88M	94.76M	99.86M	116.49M	101.12M	152.43M	135.83M	137.00M	133.10M	162.37M	174.69M	177.20M	173.25M
Selling, General & Administrative (Quarter)	18.43M	37.40M	25.00M	34.27M	33.14M	32.03M	20.98M	23.22M	23.77M	24.57M	23.61M	25.07M	23.71M	26.38M	26.91M	28.41M	30.95M	37.68M	46.02M	41.74M
Other Operating Expenses (Quarter)																				19.00M
Operating Expenses (Quarter)	77.76M	103.17M	90.76M	110.25M	105.32M	115.41M	104.68M	98.10M	118.53M	124.43M	140.10M	126.19M	176.14M	162.20M	163.91M	161.51M	193.32M	212.37M	223.22M	215.00M
Operating Income (Quarter)	-31.87M	-64.88M	-63.32M	41.55M	-72.91M	-83.83M	-42.13M	48.16M	-102.70M	-108.33M	-136.54M	-126.19M	-176.14M	-162.20M	-161.41M	381.20M	-165.55M	44.11M	40.81M	-141.26M
EBIT (Quarter)	-31.87M	-64.88M	-63.32M	41.55M	-72.91M	-83.83M	-42.13M	48.16M	-102.70M	-108.33M	-136.54M	-126.19M	-176.14M	-162.20M	-161.41M	381.20M	-165.55M	44.11M	40.81M	-141.26M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)				1.05M	1.24M	1.58M	2.68M	4.56M	4.17M	3.88M	2.80M	6.25M	6.50M	7.17M	7.60M	9.62M	11.02M	9.09M	9.70M	16.87M
Other Non Operating Income (Quarter)	0.66M	0.36M	-0.71M	1.76M	-0.38M	0.09M	0.51M	0.01M	0.31M	0.72M	0.42M	0.19M	0.76M	-3.12M	0.34M	0.44M	-0.18M	4.66M	0.28M	-1.61M
Non Operating Income (Quarter)	1.28M	1.51M	1.16M	2.81M	0.86M	1.67M	0.34M	-0.49M	-0.68M	-0.66M	-2.14M	-0.81M	2.16M	-10.60M	-13.70M	-11.59M	-13.54M	-7.99M	-12.54M	3.69M
Net income details
EBT (Quarter)	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-82.16M	-41.79M	47.68M	-103.38M	-108.99M	-138.69M	-127.00M	-173.98M	-172.80M	-175.12M	369.62M	-179.09M	36.12M	28.27M	-137.56M
Tax Provisions (Quarter)		0.00M				3.79M			0.74M	2.02M	-3.31M			0.53M	0.10M	1.75M	-0.40M	20.00M	0.03M	0.01M
Profit After Tax (Quarter)	-29.92M	-63.42M	-62.87M	44.37M	-72.05M	-86.01M	-41.81M	47.68M	-104.12M	-110.74M	-135.38M	-127.00M	-173.98M	-180.74M	-175.22M	370.70M	-178.65M	15.51M	28.24M	-139.09M
Income from Non-Controlling Interests (Quarter)						-0.43M	-0.49M	-1.00M		-0.30M	1.91M	0.22M	0.25M	1.40M	-0.51M	-2.58M	0.88M	10.25M	0.15M	-4.84M
Income from Continuing Operations (Quarter)	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.79M	47.68M	-104.12M	-111.02M	-135.38M	-127.00M	-173.98M	-173.33M	-175.22M	367.86M	-178.69M	16.12M	28.24M	-137.57M
Income from Discontinued Operations (Quarter)
Consolidated Net Income (Quarter)	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.79M	47.68M	-104.12M	-111.02M	-135.38M	-127.00M	-173.98M	-173.33M	-175.22M	367.86M	-178.69M	16.12M	28.24M	-137.57M
Income towards Parent Company (Quarter)	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.79M	47.68M	-104.12M	-111.02M	-135.38M	-127.00M	-173.98M	-173.33M	-175.22M	367.86M	-178.69M	16.12M	28.24M	-137.57M
Net Income towards Common Stockholders (Quarter)	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.79M	47.68M	-104.12M	-111.02M	-135.38M	-127.00M	-173.98M	-173.33M	-175.22M	367.86M	-178.69M	16.12M	28.24M	-137.57M
Additional items
EPS (Basic) (Quarter)	-0.29	-0.61	-0.60	0.42	-0.68	-0.82	-0.39	0.45	-0.97	-1.04	-1.26	-1.03	-1.40	-1.45	-1.40	2.76	-1.29	0.12	0.21	-0.97
EPS (Diluted) (Quarter)	-0.29	-0.61	-0.60	0.41	-0.68	-0.82	-0.39	0.44	-0.97	-1.04	-1.26	-1.03	-1.40	-1.45	-1.40	2.74	-1.29	0.12	0.20	-0.97
Shares Outstanding (Quarter)	104.10M	103.75M	104.53M	105.55M	105.75M	105.43M	106.04M	106.76M	107.00M	106.75M	107.42M	123.28M	124.20M	119.78M	124.85M	133.36M	139.04M	133.76M	137.04M	142.42M
Shares Outstanding (Diluted) (Quarter)	104.10M	103.75M	104.53M	107.93M	105.75M	105.43M	106.04M	108.14M	107.00M	106.75M	107.42M	123.28M	124.20M	119.78M	124.85M	134.48M	139.04M	133.76M	140.71M	142.42M
Shares Outstanding (Entity) (Quarter)	104.21M	104.33M	104.80M	105.70M	105.80M	105.96M	106.14M	106.87M	107.10M	107.31M	107.50M	124.13M	124.23M	124.38M	125.57M	138.06M
EBITDA (Quarter)	-31.87M	-64.88M	-63.32M	41.55M	-72.91M	-83.83M	-42.13M	48.16M	-102.70M	-108.33M	-136.54M	-126.19M	-176.14M	-162.20M	-161.41M	381.20M	-165.55M	44.11M	40.81M	-141.26M
Interest Expenses (Quarter)	224.67M	0.90M	149.31M	2.17M	1.70M	1.70M	2.85M	5.06M	147.32M	-10.86M	5.37M	7.24M	5.09M	2.10M	21.65M	21.64M	176.99M	-4.34M	169.61M	165.67M
Tax Rate (Quarter)		0.00%				-4.61%			-0.72%	-1.86%	2.39%			-0.31%	-0.06%	0.47%	0.22%	55.37%	0.10%	-0.01%

Research Tools

Developers

Arrowhead Pharmaceuticals Income Statement (2010-2026) | ARWR

Research Tools

Developers

Arrowhead Pharmaceuticals Income Statement (2010-2026) | ARWR

Create an account

Sign In

Reset Password